doi: 10.1038/d41573-022-00036-y.
LAG3 pushes immuno-oncology's leading edge
- PMID: 35177834
- DOI: 10.1038/d41573-022-00036-y
Item in Clipboard
LAG3 pushes immuno-oncology's leading edge
Nat Rev Drug Discov.
2022 Mar.
No abstract available
Similar articles
-
US Government Payer-Funded Trials to Address Oncology's Drug-Dosing Conundrum: A Congressional Call to Action?J Clin Oncol. 2023 May 10;41(14):2488-2492. doi: 10.1200/JCO.22.02049. Epub 2023 Feb 13. J Clin Oncol. 2023. PMID: 36780590 No abstract available.
-
Oncology's "Hockey Stick" Moment for the Cost of Cancer Drugs-The Climate Is About to Change.JAMA Oncol. 2021 Jan 1;7(1):25-26. doi: 10.1001/jamaoncol.2020.1828. JAMA Oncol. 2021. PMID: 33001134 No abstract available.
-
Stocking oncology's medicine cabinet.Science. 2017 Mar 17;355(6330):1142-1143. doi: 10.1126/science.355.6330.1142. Science. 2017. PMID: 28302820 No abstract available.
-
Know Your Value: Negotiation Skill Development for Junior Investigators in the Academic Environment--A Report from the American Society of Preventive Oncology's Junior Members Interest Group.Cancer Epidemiol Biomarkers Prev. 2015 Jul;24(7):1144-8. doi: 10.1158/1055-9965.EPI-15-0476. Cancer Epidemiol Biomarkers Prev. 2015. PMID: 26139841 Free PMC article. Review. No abstract available.
-
The Cancer Journal Article for Theme Issue: The Problem of Cancer Drug Costs.Cancer J. 2020 Jul/Aug;26(4):292-297. doi: 10.1097/PPO.0000000000000466. Cancer J. 2020. PMID: 32732671 Review.
Cited by
-
The expanding role for small molecules in immuno-oncology.Nat Rev Drug Discov. 2022 Nov;21(11):821-840. doi: 10.1038/s41573-022-00538-9. Epub 2022 Aug 18. Nat Rev Drug Discov. 2022. PMID: 35982333 Review.
-
LAG-3 as the third checkpoint inhibitor.Nat Immunol. 2023 Sep;24(9):1415-1422. doi: 10.1038/s41590-023-01569-z. Epub 2023 Jul 24. Nat Immunol. 2023. PMID: 37488429 Free PMC article. Review.
-
The effect of blocking immune checkpoints LAG-3 and PD-1 on human invariant Natural Killer T cell function.Sci Rep. 2023 Jun 21;13(1):10082. doi: 10.1038/s41598-023-36468-8. Sci Rep. 2023. PMID: 37344517 Free PMC article.
-
Machine learning-based on cytotoxic T lymphocyte evasion gene develops a novel signature to predict prognosis and immunotherapy responses for kidney renal clear cell carcinoma patients.Front Immunol. 2023 Jul 31;14:1192428. doi: 10.3389/fimmu.2023.1192428. eCollection 2023. Front Immunol. 2023. PMID: 37600786 Free PMC article.
-
Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials.Signal Transduct Target Ther. 2022 Oct 5;7(1):353. doi: 10.1038/s41392-022-01200-x. Signal Transduct Target Ther. 2022. PMID: 36198685 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
